Study Objectives: To determine the relationship between obstructive sleep apnea (OSA) and chronic kidney disease (CKD). Previous population studies of the association are sparse, conflicting and confined largely to studies of administrative data. Methods: Cross-sectional analysis in unselected participants of the Men Androgens Inflammation Lifestyle Environment and Stress (MAILES) study, aged >40 years. Renal data were available for 812 men without a prior OSA diagnosis who underwent full in-home polysomnography (Embletta X100) in 2010-2011. CKD was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m 2 or eGFR≥60 and albuminuria (albumin-creatinine ratio ≥3.0 mg/mmol). Results: CKD (10.5%, n = 85 [Stage 1-3, 9.7%; Stage 4-5, 0.7%]) of predominantly mild severity showed significant associations with OSA (apnea-hypoapnea index [AHI] ≥ 10): odds ratio (OR) = 1.9, 95% confidence interval (CI): 1.02-3.5; severe OSA (AHI ≥ 30/h): OR = 2.6, 95% CI: 1.1-6.2; and respiratory-related arousal index: ≥7.6/h, OR = 2.3, 95%CI: 1.1-4.7; but not measures of hypoxemia after adjustment for age, hypertension, diabetes, smoking, obesity, and NSAID use. There was no association of CKD with daytime sleepiness. In men with CKD, those with OSA were not significantly more likely to report symptoms (sleepiness, snoring, and apneas) or be identified with the STOP OSA screening questionnaire, compared to men without OSA. Conclusions: Predominantly mild CKD is associated with severe OSA and arousals. Further population studies examining the longitudinal relationship between CKD and OSA are warranted. Better methods are needed to identify OSA in CKD which may have few symptoms.
INTRODUCTION
The prevalence of chronic kidney disease (CKD) and obstructive sleep apnea (OSA) has increased over the past two decades, 1, 2 in line with population aging and increases in obesity. While studies in renal clinical populations report an association between OSA and CKD, 3 they are limited by selective recruitment due to referral bias and confounding, with a bias to inclusion of those with conditions such as hypertension, obesity, and diabetes that are also significantly associated with OSA.
Evidence from the few population studies is mixed. In the Swiss HypnoLaus study, CKD was related to objective sleep efficiency but not moderate-severe OSA after adjustment for age and obesity. 4 In the Three City (3C) study, a French population study of adults aged at least 65 years, severe OSA was independently associated with estimated glomerular filtration rate (eGFR) decline over 11 years, but relationships with measures of nocturnal hypoxemia were mot seen. 5 In a population-based study of older men (aged at least 67), independent associations between the respiratory disturbance index eGFR 6 and microalbuminuria 7 were not seen although greater nocturnal hypoxemia was independently associated with albuminuria. 7 In retrospective case-control studies using Taiwanese administrative data, relationships of OSA with incident CKD were seen overall 8 and in men, 9 but OSA wasn't associated with an increased incidence of end-stage kidney disease (ESKD) in men. 9 However, data were unavailable regarding the severity of OSA, obesity, smoking, and medication history (including nonsteroidal anti-inflammatory drugs [NSAIDs]) 9 which may impact on understanding the relationship of OSA with CKD. 10 In a large administrative database of U.S. veterans, a diagnosis of incident OSA was associated with CKD and with faster decline in kidney function, but OSA severity was not available. 11 Given that OSA 12 and kidney disease 13 remain largely undiagnosed, ascertainment and misclassification bias is likely to affect the case and control groups in administrative database studies, leading to possible incorrect estimates of an association. The question arises whether the association between CKD and OSA is confined to those with significant OSA symptoms who are more likely to be investigated and diagnosed. However, OSA in CKD patients is often not associated with sleep-related symptoms. 14 
Statement of Significance
In a population sample of community-dwelling men aged at least 40 years without a prior OSA diagnosis, we have demonstrated a cross-sectional association of CKD of mild severity (Stage 3 or less) with OSA and respiratory-related arousals for the first time. The mild nature of the CKD in our study suggests mechanisms leading to kidney damage involving intrarenal hypoxia and activation of the systemic and renal renin-angiotensin system. OSA in men with CKD was asymptomatic indicating the need for novel screening methods to identify OSA. Population studies examining the longitudinal relationship between CKD and OSA are required. Intervention studies in OSA patients at risk of developing CKD are required to determine whether OSA treatment preserves renal function.
OSA may contribute to CKD 15 through a direct effect of intrarenal hypoxia on the kidney and activation of the systemic and renal renin-angiotensin system (RAS).
14 Nocturnal hypoxemia has been associated with higher urinary albumin excretion. 7 OSA-related hypertension 16 and cardiovascular disease 17 may have detrimental effects on kidney function. Renal hemodynamics can improve with OSA treatment with downregulation of renal RAS activity. 18, 19 However, ESKD may increase the risk of OSA through pharyngeal narrowing due to fluid overload, and alteration in chemoreflex responsiveness resulting in destabilization of the control of breathing during sleep. 20 Determining whether OSA is independently associated with CKD may have significant implications for clinical practice and population health in efforts to reduce the burden of CKD. Therefore, the aim of this study was to examine cross-sectional associations of objectively determined OSA and kidney disease in a biomedical cohort of community-dwelling men. We also examined whether any association between CKD and OSA was confined to those with significant OSA-related symptoms.
MATERIALS AND METHODS

Study Participants
The Men Androgen Inflammation Lifestyle Environment and Stress (MAILES) study 21 is comprised of randomly selected community-dwelling ambulatory men aged at least 35 years at baseline (2002) (2003) (2004) (2005) (2006) , of largely Australian or European descent (96%), participating in the North West Adelaide Health Study (NWAHS) or Florey Adelaide Male Aging Study (FAMAS). Biomedical assessment was conducted using standardized and reproducible study protocols. Appointments were rescheduled if participants were suffering from acute illnesses. Detailed demographic, biographical, self-reported co-morbidities, and risk factor information was collected via computer-assisted telephone interviews (CATI) and self-completed questionnaires. Approval for the MAILES study was obtained from the Human Research Ethics Committees of the North West Adelaide Health Service and Royal Adelaide Hospital (approval numbers: 2010054, 02305H). All participants gave written informed consent.
Sleep Data
Of MAILES study participants completing a CATI survey in August 2010 (n = 1629), 184 (11.3%) reported "yes" to "Have you ever been diagnosed with obstructive sleep apnea with a sleep study?" The 1445 men responding "no" were invited to undergo a sleep study, with 75.2% agreeing. By the conclusion of the study period (2010-2011), 837 men successfully completed eight-channel, in-home unattended polysomnography (PSG; Embletta X100, Embla Systems, Broomfield, CO, USA) as previously described. 22 The Epworth Sleepiness Scale, 23 STOP questionnaire, 24 29 We used percentage of sleep time with oxygen saturation <90% (TST90) and oxygen desaturations of ≥3% per hour (ODI 3%) as indicators of nocturnal hypoxemia and the total arousal index and respiratory-related arousals (apnea, hypopnea, and respiratory effort related) as indicators of sleep fragmentation.
Renal Function
Urine albumin was quantified by immunoturbidimetric assay (OSR6167, Beckman Coulter, Brea, California), and the IDMS traceable Kinetic Jaffe (compensated) method was used for the quantitative determination of creatinine in serum or urine (OSR6578, Beckman Coulter). All renal measures for NWAHS participants were determined by an Olympus AU5400 autoanalyzer (Olympus Corp, Tokyo, Japan) and by a Roche Diagnostic autoanalyzer, (Mannheim, Germany) for FAMAS participants.
The recommended Chronic Kidney Disease Epidemiology Collaboration equation 30 
Chronic Condition Covariates
Clinic assessment (2007-2010) included measurement of height, weight, waist circumference, and blood pressure, and a fasting blood sample was drawn for creatinine, glucose, glycated hemoglobin and lipid measurements. Urinalysis determined creatinine and albumin (NWAHS participants). Blood pressure was measured using a standard, calibrated sphygmomanometer. Two measurements were taken 5 to 10 minutes apart while the participant was relaxed and seated, and the mean of the two measurements was calculated. Hypertension was defined as systolic pressure ≥140 mmHg and/or diastolic pressure ≥90 mmHg or medication use. Diabetes was determined by a self-report of doctor diagnosed diabetes, fasting plasma glucose ≥7.0 mmol/L, glycated hemoglobin ≥6.5%, or diabetes medication use. Cardiovascular disease/stroke was identified by a self-report of doctor diagnosed myocardial infarction, angina, stroke or transient ischemic attack. Body mass index (BMI; kg/m 2 ) was categorized according to international criteria-underweight/ normal: ≤24.9, overweight: 25.0-29.9, and obese: ≥30.0.
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Statistical Analysis
Data were analyzed using SPSS version 20.0 (IBM Corporation, Armonk, NY, USA). Univariate associations of CKD with demographics, risk factors, and PSG indices of OSA or selfreported OSA including clinical categories of total AHI and ODI 3% and tertiles of total and respiratory-related arousal index and TST90 were determined with the Pearson chi-square or linear-by-linear association statistic (Mantel-Haenszel) for testing the presence of a linear trend. OSA symptoms were examined in relation to CKD and OSA status with Pearson chi -square tests. Logistic regression analyses identified associations of CKD (compared to normal renal function) with OSA and PSG indices adjusted for variables including age, BMI, smoking history, diabetes, hypertension (categorical or as continuous variables), education, and NSAID use. The modification of relationships between OSA and CKD by hypertension, diabetes, education level, or lag time between renal function assessment and the sleep study were determined by the inclusion of interaction terms in the logistic regression model. In addition, for each OSA parameter, we examined a collection of nonlinear functional forms including log, square-root, quadratic, and cubic. Akaike information criteria (AIC) and log-likelihood ratio (LLR) tests were performed for models with and without the OSA parameters.
RESULTS
Measures of serum creatinine and urine ACR were available in 1543 of 1629 men undergoing CATI assessment. Table 1 shows the distribution of study participants across eGFR and ACR clinical categories.
Renal function data were available in 986 men, mean age (SD) = 58.7 (10.7), whose OSA status was ascertained by PSG (n = 812) or by self-report of previously diagnosed sleep apnea (n = 174). The prevalence of CKD was 11.0% (95% CI: 9.1-13.0, n = 109). Consistent with recent international findings, 33 the prevalence of OSA (AHI ≥10/h) was 52.1% and present in 48.9% of men with normal renal function, 52.4% in those with mildly reduced Egfr, and 65.9% in CKD (p = .017). AHI ≥10/h or self-reported previously diagnosed OSA also increased significantly across renal function categories (57.3%, 60.9%, and 73.4% in those with normal renal function, mildly reduced eGFR, and CKD, respectively, p = .008).
Renal function in relation to demographic and biomedical characteristics of men whose OSA status was known is shown in Table 2 . CKD was associated with hypertension, diabetes, NSAID use, cardiovascular disease, workforce nonparticipation, and household income <$40 000/year after adjustment for age. In logistic regression models, significant associations of CKD persisted with age, diabetes, and smoking (current and former). Table 3 shows OSA clinical features in relation to OSA and CKD status. Overall, men with OSA were more likely to be snoring loudly at least 3 nights/week and be identified by the STOP questionnaire than men without OSA. However, in men with CKD, those with OSA were not significantly more likely to report OSA symptoms (sleepiness, snoring, apneas, nocturia) or be identified with the STOP OSA screening questionnaire, compared to men without OSA. In men with OSA, those with CKD reported significantly more nocturia symptoms but significantly less snoring than men without CKD. Table 4 shows renal function in relation to PSG indices in 812 men, mean age (SD) = 58.3 (10.8). The prevalence of CKD in eating, socializing at least once per week; (2) sleepy during day/evening-yes response to "Do you feel sleepy when sitting quietly during the day or early evening?" compared to "sometimes/no"; (3) STOP Questionnaire item 2-Yes response to "Do you often feel tired, fatigued or sleepy during daytime?", compared to no/don't know response. e STOP Questionnaire item 3-yes response to "Has anyone observed you stop breathing during your sleep?" f Pittsburgh Sleep Quality Index question 21: If you have a bed partner/share a room, ask him/her how often in the past month you have had loud snoring? g p < .05 for differences in symptom in CKD compared to men without CKD in men with OSA. h p < .05 for differences in symptom in CKD compared to men without CKD in men without OSA. arousal index add explanatory value to the variation in the risk of CKD. In the fully adjusted models, the model with AHI as a linear variable had the same AIC as the null model, and the smallest AICs were observed with log transformed AHI (1 degree of freedom [df] ) and the cubic (3 df) AHI, with the LLR tests for both being marginally significant (p = .04 and p = .05, respectively). Examination of the association between AHI and the linear predictor (log odds ratio) indicates that risk of CKD increases with AHI until around AHI = 30 and then remains on a plateau for AHI >30. The fully adjusted model containing the log-transformed, respiratory-related arousal index generated the smallest AIC with the LLR test being significant (p = .04). ODI (3%) was associated with CKD when adjusted for age but was no longer significant in fully adjusted models (LLR test p value = .09). Stage 1 CKD or higher was significantly more common in men with a prior OSA diagnosis (13.8%, n = 24, p < .01) compared to men with AHI <10 (7.4%, n = 29). However, in adjusted models including age, diabetes, hypertension, obesity, and smoking, associations of CKD did not persist with self-reported previously diagnosed OSA (OR = 1.1, 95% CI: 0.5-2.5).
Total
There was no evidence of modification of the CKD-OSA association by hypertension ([multiple] adjusted p for interaction = .44), diabetes (p for interaction = .96), or lag between renal function and OSA assessment (p for interaction = .95). No significant interactions were observed between TST90 and hypertension (p = .94) or diabetes (p = .38). Similarly, no significant interactions were observed between respiratory-related arousal index and hypertension (p = .92) or diabetes (p = .21). The reported associations were unchanged when continuous blood pressure variables were included in the models.
DISCUSSION
In a population sample of community-dwelling men with objectively measured OSA, we observed significant, independent cross-sectional associations of OSA and sleep fragmentation with CKD, which was predominantly Stage 1-3 severity. Previous studies in clinic samples 3, 14 and administrative data 9 have shown independent associations between OSA and more severe CKD, particularly ESRD. Our results support findings by Molnar et al., 11 Chu et al., 8 and Lee et al. 9 using administrative data only from patients with diagnosed with OSA, where referral bias may have influenced the findings of an association of OSA and CKD. By considering both diagnosed OSA and OSA that was previously undiagnosed in men until the present study, we have addressed some of these concerns. Previously undiagnosed OSA (but not self-reported diagnosed OSA) was independently associated with CKD. Furthermore, compared to men with CKD alone, those with both CKD and OSA were not significantly more likely to report OSA symptoms (sleepiness, snoring, apneas, nocturia) or to be identified with the STOP OSA screening questionnaire, but the small sample size of the CKD limited our ability to detect this effect. Thus, our findings confirm that the CKD-OSA relationship is not confined to symptomatic OSA, which is more likely to be diagnosed. Differences in our findings with those of Ogna et al. 4 from a population-based sample may be explained by their use of the more liberal 2012 sleep study scoring criteria (compared with our stricter 2007 alternative criteria) and of definitions of moderate-severe OSA (AHI ≥15/hr compared to ≥20/hr in our study). This approach produced a higher prevalence of OSA in the Ogna et al. sample and may have reduced the apparent effect of OSA on CKD in adjusted analyses.
CKD, particularly ESKD, may be a risk factor for OSA. 20 Unstable ventilatory control, 34 and altered chemoreflex responsiveness in patients with ESKD, can contribute to breathing instability during sleep. Further, renal impairment-related fluid accumulation may lead to pharyngeal narrowing increasing the risk of OSA. 35, 36 However, very few of our study participants had Stage 4 or 5 kidney disease (0.1%), suggesting that ESKDrelated effects are unlikely to account for the significant association of CKD with OSA in our study.
The kidney is vulnerable to hypoxia. Recurrent nocturnal hypoxemia due to OSA may contribute to CKD via renal tissue hypoxia with multiple intrarenal consequences on renal function and through effects on sympathetic nervous system activation, hypertension, low-grade systemic inflammation, oxidative stress, accelerated atherosclerosis, endothelial dysfunction, and activation of renal RAS. 20, 37 However, OSA may activate the sympathetic nervous system through additional mechanisms other than intermittent hypoxia. Both recurrent apneas with associated intrathoracic pressure changes 38 and subsequent frequent arousals from sleep 39 can cause increased sympathetic nerve activity and transient increases in blood pressure. Intermittent nocturnal hypoxemia and recurrent arousals are likely to activate several mechanisms that can act synergistically to amplify independent effects. 40 Although cortical arousals in OSA can quickly correct respiratory events, changes following arousal may be deleterious, tending to prolong blood-gas disturbances and breathing instability in some people. 41 We found that frequency of arousals but not hypoxemia were significantly associated with CKD.
OSA is a heterogeneous condition depending on which feature predominates-frequency of arousals, severity of hypoxia, or sleep disturbance. The clinical consequences of OSA may vary greatly across individuals, and further work is needed to better define the OSA phenotypes that may place individuals at risk of worsening renal function and associated cardiovascular risk.
The strengths of this study include the initial random recruitment of community-dwelling men derived from a broad socioeconomic base. Data were available on the stage of CKD and important comorbidities contributionng to CKD, including BMI, NSAIDs, smoking, and both diagnosed and undiagnosed diabetes and hypertension. Sampling bias is unlikely to have significantly influenced the main findings, as although sleep study participants were slightly younger and reported better general health, they were similar to nonparticipants in a number of other variables known to impact renal disease and OSA. OSA status was ascertained by PSG rather than administrative data which is subject to referral bias as most people with OSA in community cohorts do not have excessive daytime sleepiness 33, 42 and remain undiagnosed. This study is limited by the small number of cases of CKD identified at one time point, yet significant associations were nevertheless observed, albeit with sometimes wide CIs that bordered on statistical significance in fully adjusted models. However, given that OSA has been associated with the development of CKD risk factors including diabetes 43 and hypertension, 44 the true impact of OSA on CKD may be underestimated when adjusting for these conditions. In regard to these OSA-related comorbidities, the Sleep Heart Health Study demonstrated an increased mortality in younger (<70 years) but not older men with OSA. 45 This suggests that a survivor effect may be present and that our findings may be an underestimation of the effect of OSA on CKD, particularly if those with milder levels of OSA progress to late stages of CKD (4 or 5) and those with more severe OSA die earlier due to OSA-related comorbidities. Thus, the results need to be interpreted with caution. In addition, guidelines recommend that only albuminuria that persists for at least 3 months be considered diagnostic of CKD and therefore the on-off measure of ACR used in this study may lead to an overestimation of the CKD prevalence. We do not have information on OSA treatment in the self-reported previously diagnosed OSA group. OSA treatment may possibly explain a lack of a significant association of CKD with previously diagnosed OSA; however, while a significant univariate association was found, adjusting for age negated this association. A limited number of studies with small sample sizes have found improvements in filtration fraction (a marker of glomerular hypertension) 18 and blood pressure and aldosterone 19 with continuous positive airways pressure (CPAP) treatment for OSA. However, there are no clinical trials showing that CPAP can modify or improve clinical outcomes, such as the prevalence of CKD or progression to ESKD. Therefore, any potential effect of CPAP on CKD among men with a previous diagnosis of OSA in our sample is unknown. If the effect of CPAP was to reduce CKD, then, if anything, this would tend to reduce the association of OSA and CKD. Our cross-sectional study prevents the ascribing of causality in the OSA-CKD relationship.
Further work is needed to delineate the pathophysiological pathways linking OSA and CKD. However, available evidence indicates that clinicians should emphasize management that can delay progression of CKD, including blood pressure control, smoking cessation, and other lifestyle modifications and medications that may reduce proteinuria. 46 The clinical utility of screening for OSA (which may be asymptomatic) across all stages of chronic kidney disease with novel strategies warrants further study, given current screening questionnaires do not accurately identify patients at high risk of OSA in CKD or ESKD. 47 Studies examining whether management of OSA may delay progression to CKD are also warranted.
